21May 2024
Vedolizumab and Infliximab Equally Effective for Ulcerative Colitis

Vedolizumab and Infliximab Equally Effective for Ulcerative Colitis

A study assessed vedolizumab (VDZ) and infliximab (IFX) efficacy and safety in biologic-naïve patients with moderate-to-severe ulcerative colitis (UC). The study included 122 patients. Both VDZ and IFX demonstrated similar steroid-free clinical remission rates and clinical remission rates at Weeks 14 and 52 (P > 0.05). While VDZ showed a higher mucosal healing rate at Week 14 compared to IFX, differences were insignificant by Week 52. Adverse event rates did not significantly differ between the two groups. The findings suggest VDZ and IFX as viable first-line therapies for biologic-naïve patients with moderate-to-severe UC.

  • #gastroenterology

Like

Save

Share